Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18807211 | 1.00 | HTR2C (0.39) | HTR2CHTR2AHTR2BHRH2HRH3 | |
| SCHEMBL1424574 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL29532721 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL4123694 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL15267245 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL12583743 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL30666992 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL379328 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL17768626 | 0.78 | HTR2A (0.39) | HTR2CHTR2AHTR2BFNTAFNTB | |
| SCHEMBL15267240 | 0.77 | HTR2B (0.37) | HTR2CHTR2AHTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134035-B | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12043614-B2 | Salts of a Pim kinase inhibitor | INCYTE CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20180170907-A1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORPORATION | 2018-06-21 | — | — | US | disclosed |
| US-9862705-B2 | Salts of a pim kinase inhibitor | INCYTE CORPORATION (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170121310-A1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORPORATION | 2017-05-04 | — | — | US | disclosed |
| EP-2185541-B1 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170907-A1 | SALTS OF A PIM KINASE INHIBITOR | PIM1, PIM3, PIM2 | HTR2C 3112/4885HTR2A 4423/4885HTR2B 4040/4885 |
| US-20170121310-A1 | SALTS OF A PIM KINASE INHIBITOR | PIM1, PIM3, PIM2 | HTR2C 3112/4885HTR2A 4423/4885HTR2B 4040/4885 |
| US-12043614-B2 | Salts of a Pim kinase inhibitor | PIM1, PIM3, PIM2 | HTR2C 3112/4885HTR2A 4423/4885HTR2B 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.